Design and in silico investigation of novel Maraviroc analogues as dual inhibition of CCR-5/SARS-CoV-2 M^pro

References

• Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25. https://doi.org/10.1016/j.softx.2015.06.001
   Google Scholar
• Ahidjo, B. A., Loe, M., Ng, Y. L., Mok, C. K., & Chu, J. J. H. (2020). Current perspective of antiviral strategies against COVID-19. ACS Infectious Diseases, 6(7), 1624–1634. https://doi.org/10.1021/acsinfecdis.0c00236
   PubMed Web of Science ®Google Scholar
• Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., & Berger, E. A. (1996). CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (New York, N.Y.), 272(5270), 1955–1958. https://doi.org/10.1126/science.272.5270.1955
   PubMed Web of Science ®Google Scholar
• Al-Sehemi, A. G., Pannipara, M., Patil, O., Parulekar, R. S., Choudhari, P. B., Bhatia, M. S., Zubaidha, P. K., & Tamboli, Y. (2020). Potentials of NO donor Furoxan as SARS-CoV-2 main protease (Mpro) inhibitors: In silico analysis. Journal of Biomolecular Structure and Dynamics, https://doi.org/10.1080/07391102.2020.1790038
   Google Scholar
• Alves, V. M., Bobrowski, T., Melo‐Filho, C. C., Korn, D., Auerbach, S., Schmitt, C., Muratov, E. N., & Tropsha, A. (2021). QSAR modeling of SARS‐CoV Mpro inhibitors identifies sufugolix, cenicriviroc, proglumetacin, and other drugs as candidates for repurposing against SARS‐CoV‐2. Molecular Informatics, 40(1), 2000113. https://doi.org/10.1002/minf.202000113
   PubMed Web of Science ®Google Scholar
• Amadei, A., Linssen, A. B., & Berendsen, H. J. (1993). Essential dynamics of proteins. Proteins Struct Proteins, 17(4), 412–425. https://doi.org/10.1002/prot.340170408
   PubMed Web of Science ®Google Scholar
• Amin, M., Sorour, M. K., & Kasry, A. (2020). Comparing the binding interactions in the receptor binding domains of SARS-CoV-2 and SARS-CoV. The Journal of Physical Chemistry Letters, 11(12), 4897–4900. https://doi.org/10.1021/acs.jpclett.0c01064
   PubMed Web of Science ®Google Scholar
• Barale, S. S., Parulekar, R. S., Fandilolu, P. M., Dhanavade, M. J., & Sonawane, K. D. (2019). Molecular insights into destabilization of Alzheimer’s Aβ protofibril by arginine containing short peptides: A molecular modeling approach. ACS Omega , 4(1), 892–903. https://doi.org/10.1021/acsomega.8b02672
   Web of Science ®Google Scholar
• Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., & Perros, M. (2005). Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrobial Agents and Chemotherapy, 49(11), 4721–4732. https://doi.org/10.1128/AAC.49.11.4721-4732.2005
   PubMed Web of Science ®Google Scholar
• Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., & Pedersen, L. G. (1995). A smooth particle mesh Ewald method. The Journal of Chemical Physics, 103(19), 8577–8593. https://doi.org/10.1063/1.470117
   Web of Science ®Google Scholar
• Gahlawat, A., Kumar, N., Kumar, R., Sandhu, H., Singh, I. P., Singh, S., Sjöstedt, A., & Garg, P. (2020). Structure-based virtual screening to discover potential lead molecules for the SARS-CoV-2 main protease. Journal of Chemical Information and Modeling, 60(12), 5781–5793. https://doi.org/10.1021/acs.jcim.0c00546
   PubMed Web of Science ®Google Scholar
• Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. A., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., & Martínez, A. (2020). COVID-19: Drug targets and potential treatments. Journal of Medicinal Chemistry, 63(21), 12359–12386. https://doi.org/10.1021/acs.jmedchem.0c00606
   PubMed Web of Science ®Google Scholar
• Gómez, J., Cuesta-Llavona, E., Albaiceta, G. M., García-Clemente, M., López-Larrea, C., Amado, L., López-Alonso, I., Hermida, T., Enriquez, A., Gil, H., & Alonso, B. (2020). The CCR5-delta32 variant might explain part of the association between COVID-19 and the chemokine-receptor gene cluster. medRxiv. https://doi.org/10.1101/2020.11.02.20224659
   Google Scholar
• Goyal, B., & Goyal, D. (2020). Targeting the dimerization of the main protease of coronaviruses: A potential broad-spectrum therapeutic strategy. ACS Combinatorial Science, 22(6), 297–305. https://doi.org/10.1021/acscombsci.0c00058
   PubMed Web of Science ®Google Scholar
• Hess, B., Bekker, H., Berendsen, H. J., & Fraaije, J. G. (1997). LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18(12), 1463–1472. https://doi.org/10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Web of Science ®Google Scholar
• https://www.rcsb.org/structure/6W63 https://www.worldometers.info/coronavirus/
   Google Scholar
• Huynh, T., Wang, H., & Luan, B. (2020). In silico exploration of molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2's main protease. The Journal of Physical Chemistry Letters, 11(11), 4413–4420. https://doi.org/10.1021/acs.jpclett.0c00994
   PubMed Web of Science ®Google Scholar
• Kaminski, G. A., Friesner, R. A., Tirado-Rives, J., & Jorgensen, W. L. (2001). Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. The Journal of Physical Chemistry B, 105(28), 6474–6487. ‎ https://doi.org/10.1021/jp003919d
   Web of Science ®Google Scholar
• Khan, S. A., Zia, K., Ashraf, S., & Uddin, R. (2021). Ul-Haq, Z. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. Journal of Biomolecular Structure and Dynamics, 39(7), 2607–2616. https://doi.org/10.1080/07391102.2020.1751298
   Google Scholar
• Kliger, Y., Levanon, E. Y., & Gerber, D. (2005). From genome to antivirals: SARS as a test tube. Drug Discovery Today, 10(5), 345–352. https://doi.org/10.1016/S1359-6446(04)03320-3
   PubMed Web of Science ®Google Scholar
• Kumar, S., Sharma, P. P., Shankar, U., Kumar, D., Joshi, S. K., Pena, L., Durvasula, R., Kumar, A., Kempaiah, P., & Rathi, B. (2020). Discovery of new hydroxyethylamine analogs against 3CLpro protein target of SARS-CoV-2: Molecular docking, molecular dynamics simulation and structure-activity relationship studies. Journal of Chemical Information and Modeling, 60(12), 5754–5770. https://doi.org/10.1021/acs.jcim.0c00326
   Google Scholar
• Kumari, R., Kumar, R., & Lynn, A. (2014). g_mmpbsa-A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Lee, V. S., Chong, W. L., Sukumaran, S. D., Nimmanpipug, P., Letchumanan, V., Goh, B. H., Lee, L. H., Zain, S. M., & Abd Rahman, N. (2020). Computational screening and identifying binding interaction of anti-viral and anti-malarial drugs: Toward the potential cure for SARSCoV-2. Progress in Drug Discovery & Biomedical Science, 3(1), 1–9. https://doi.org/10.36877/pddbs.a0000065
   Google Scholar
• MacArthur, R. D., & Novak, R. M. (2008). Reviews of anti-infective agents: Maraviroc: The first of a new class of antiretroviral agents. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 47(2), 236–241. https://doi.org/10.1086/589289
   PubMed Web of Science ®Google Scholar
• Mamidala, E., Davella, R., Gurrapu, S., & Shivakrishna, P. (2020). In silico identification of clinically approved medicines against the main protease of SARS-CoV-2, causative agent of covid-19. arXiv:2004.12055
   Google Scholar
• Mohanta, T. K., Arina, P., Sharma, N., & Defilippi, P. (2020). Role of azithromycin in antiviral treatment: Enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade? American Journal of Translational Research, 12, 7702.
   PubMed Web of Science ®Google Scholar
• Mohanta, T. K., Sharma, N., Arina, P., & Defilippi, P. (2020). Molecular insights into the MAPK cascade during viral infection: Potential crosstalk between HCQ and HCQ analogues. Biomed Research International, 2020, 1–9. https://doi.org/10.1155/2020/8827752
   Web of Science ®Google Scholar
• Ngo, S. T., Pham, N. Q. A., Le, L., Pham, D. H., & Vu, V. (2020). Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease. Journal of Chemical Information and Modeling, 60(12), 5771–5780. https://doi.org/10.1021/acs.jcim.0c00491
   PubMed Web of Science ®Google Scholar
• Okamoto, M., Toyama, M., & Baba, M. (2020). The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 182, 104902. https://doi.org/10.1016/j.antiviral.2020.104902
   PubMed Web of Science ®Google Scholar
• Papaleo, E., Mereghetti, P., Fantucci, P., Grandori, R., & De Gioia, L. (2009). Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: The myoglobin case. Journal of Molecular Graphics & Modelling, 27(8), 889–899. https://doi.org/10.1016/j.jmgm.2009.01.006
   PubMed Web of Science ®Google Scholar
• Parulekar, R. S., & Sonawane, K. D. (2018). Insights into the antibiotic resistance and inhibition mechanism of aminoglycoside phosphotransferase from Bacillus cereus: In silico and in vitro perspective. Journal of Cellular Biochemistry, 119(11), 9444–9461. ‐https://doi.org/10.1002/jcb.27261
   PubMed Web of Science ®Google Scholar
• Parulekar, R. S., & Sonawane, K. D. (2018). Molecular modeling studies to explore the binding affinity of virtually screened inhibitor toward different aminoglycoside kinases from diverse MDR strains. Journal of Cellular Biochemistry, 119(3), 2679–2695. https://doi.org/10.1002/jcb.26435
   PubMed Web of Science ®Google Scholar
• Patterson, B. K., Seethamraju, H., Dhody, K., Corley, M. J., Kazempour, K., Lalezari, J. P., Pang, A. P., Sugai, C., Francisco, E. B., Pise, A., & Rodrigues, H. (2020). Disruption of the CCL5/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19. medRxiv, https://doi.org/10.1101/2020.05.02.20084673
   Google Scholar
• Shamsi, A., Mohammad, T., Anwar, S., Alajmi, M., Hussain, A., Rehman, M., Islam, A., & Hassan, M. (2020). Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible therapeutic implication in COVID-19. Bioscience Reports, 40(6), BSR20201256. https://doi.org/10.1042/BSR20201256
   Google Scholar
• Sheahan, T., Morrison, T. E., Funkhouser, W., Uematsu, S., Akira, S., Baric, R. S., & Heise, M. T. (2008). MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathogens, 4(12), e1000240. https://doi.org/10.1371/journal.ppat.1000240
   PubMed Web of Science ®Google Scholar
• Sorbera, L. A., Graul, A. I., & Dulsat, C. (2020). Taking aim at a fast-moving target: Targets to watch for SARS-CoV-2 and COVID-19. Drugs of the Future, 45(4), 239–244. https://doi.org/10.1358/dof.2020.45.4.3150676
   Web of Science ®Google Scholar
• Subramanian, B., Adolfo, B. P., & Ponmalai, K. (2021). Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. Journal of Biomolecular Structure and Dynamics, 39(9), 3409–3418. https://doi.org/10.1080/07391102.2020.1758788
   Google Scholar
• Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G. W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., Zhang, W., Xie, X., Yang, H., Jiang, H., Cherezov, V., Liu, H., Stevens, R. C., Zhao, Q., & Wu, B. (2013). Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science (New York, N.Y.), 341(6152), 1387–1390. https://doi.org/10.1126/science.1241475
   PubMed Web of Science ®Google Scholar
• Van Aalten, D. M., Bywater, R., Findlay, J. B., Hendlich, M., Hooft, R. W., & Vriend, G. (1996). PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. Journal of Computer-Aided Molecular Design, 10(3), 255–262. https://doi.org/10.1007/BF00355047
   PubMed Web of Science ®Google Scholar
• Wang, H., He, S., Deng, W., Zhang, Y., Li, G., Sun, J., Zhao, W., Guo, Y., Yin, Z., Li, D., & Shang, L. (2020). Comprehensive insights into the catalytic mechanism of middle east respiratory syndrome 3C-like protease and severe acute respiratory syndrome 3C-like protease. ACS Catalysis, 10, 5871–5890. https://doi.org/10.1021/acscatal.0c00110
   PubMed Web of Science ®Google Scholar
• Wang, J. (2020). Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. Journal of Chemical Information and Modeling, 60(6), 3277–3286. https://doi.org/10.1021/acs.jcim.0c00179
   PubMed Web of Science ®Google Scholar
• Wang, R., Hozumi, Y., Yin, C., & Wei, G. W. (2020). Decoding SARS-CoV-2 transmission, evolution and ramification on COVID-19 diagnosis, vaccine, and medicine. Journal of Chemical Information and Modeling, 60(12), 5853–5865. https://doi.org/10.1021/acs.jcim.0c00501
   PubMed Web of Science ®Google Scholar
• WHO. (2020). Novel Coronavirus(2019-nCoV) situation report.
   Google Scholar
• Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G. F., Anand, K., Bartlam, M., Hilgenfeld, R., & Rao, Z. (2003). The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 100(23), 13190–13195. https://doi.org/10.1073/pnas.1835675100
   PubMed Web of Science ®Google Scholar
• Yousefi, R., & Moosavi-Movahedi, A. A. (2020). Achilles' heel of the killer virus: The highly important molecular targets for hitting SARS-CoV-2 that causes COVID-19. Journal of the Iranian Chemical Society, 17(6), 1257–1258. https://doi.org/10.1007/s13738-020-01939-6
   Web of Science ®Google Scholar
• Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science (New York, N.Y.), 368(6489), 409–412. https://doi.org/10.1126/science.abb3405
   PubMed Web of Science ®Google Scholar